Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Idorsia gets share of ponesimod and cadazolid revenues from Actelion

Executive Summary

Idorsia Pharmaceuticals Ltd. entered a revenue sharing agreement with Actelion Pharmaceuticals Ltd., from which it spun off earlier this year. The arrangement relates to Actelion's ponesimod and cadazolid, which were not included in the discovery operations and certain early clinical development assets Actelion previously divested to Idorsia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies